Stock 000952 HUBEI GUANGJI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Hubei Guangji Pharmaceutical Co., Ltd. Share Price

Equities

000952

CNE0000010R5

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 29/04/2024 BST 		5-day change 1st Jan Change
5.9 CNY +2.97% Intraday chart for Hubei Guangji Pharmaceutical Co., Ltd. +7.27% -26.16%
04-25 Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-25 Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2022 798M 111M 8.81B Sales 2023 738M 102M 8.15B Capitalization 2.83B 392M 31.25B
Net income 2022 50M 6.93M 552M Net income 2023 -140M -19.41M -1.55B EV / Sales 2022 3.69 x
Net Debt 2022 232M 32.17M 2.56B Net Debt 2023 521M 72.17M 5.75B EV / Sales 2023 4.54 x
P/E ratio 2022
53.6 x
P/E ratio 2023
-20.2 x
Employees 1,256
Yield 2022 *
-
Yield 2023
-
Free-Float 62.86%
More Fundamentals * Assessed data

Chart Hubei Guangji Pharmaceutical Co., Ltd.

Dynamic Chart

Latest news about Hubei Guangji Pharmaceutical Co., Ltd.

Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Guangji Pharmaceutical Gets Nod to Produce Entecavir MT
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Guangji Pharma to Establish Joint Innovation Laboratory With Jiangnan University MT
Guangji Pharma to Borrow 281 Million Yuan From Bank to Support Acquisition Deals MT
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hubei Guangji Pharmaceutical Announces Profit Distribution Proposal for 2022 CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Guangji Pharma Registers Diabetes-Related Infection Drug MT
Hubei Guangji Pharma to Invest 468 Million Yuan in Parkson Biotechnology Amid Bankruptcy Reorganization MT
Hubei Guangji Pharma Signs 6MW Solar Power Project MT
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Guangji Pharmaceutical Unit to Resume Production After Three-Month Stoppage MT
More news

Quotes and Performance

1 day+2.97%
1 week+7.27%
1 month-1.99%
3 months+17.06%
6 months-26.16%
Current year-26.16%
More quotes

Highs and lows

1 week
5.73
Extreme 5.73
6.05
1 month
4.89
Extreme 4.89
6.05
Current year
4.11
Extreme 4.11
8.29
1 year
4.11
Extreme 4.11
8.80
3 years
4.11
Extreme 4.11
9.09
5 years
4.11
Extreme 4.11
10.08
10 years
4.11
Extreme 4.11
23.09
More quotes

Managers and Directors - Hubei Guangji Pharmaceutical Co., Ltd.

Managers TitleAgeSince
Shu Ruan CEO
 Chief Executive Officer 48 21/04/21
Ming Feng Hu DFI
 Director of Finance/CFO 54 13/09/16
Zheng Dong Lu CTO
 Chief Tech/Sci/R&D Officer 47 -
Members of the board TitleAgeSince
Qing Yuan Li BRD
 Director/Board Member 47 21/04/21
Shao Zhi Guo BRD
 Director/Board Member 55 05/01/15
Zhong Yi Ruan PRN
 Corporate Officer/Principal 60 -
More insiders

Quotes

Date Price Change Volume
30/04/24 5.9 +2.97% 10,140,140
29/04/24 5.73 +4.18% 4,830,640

End-of-day quote Shenzhen S.E., April 29, 2024

More quotes

Company Profile

Hubei Guangji Pharmaceutical Co., Ltd. is the Chinese leader of pharmaceutical ingredients production. The group's activity is organized around four product families: - vitamins: riboflavin and beta carotene; - food supplements; - fine chemistry products; - medicinal preparations.
Sector
Pharmaceuticals
Calendar
29/05/2024 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HUBEI GUANGJI PHARMACEUTICAL CO., LTD. Stock Hubei Guangji Pharmaceutical Co., Ltd.
-26.16% 288M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 662B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 000952 Stock